Valdecoxib Is Associated with Improved Dyspepsia-Related Health Compared with Nonspecific NSAIDs in Patients with Osteoarthritis or Rheumatoid Arthritis
暂无分享,去创建一个
L. Rabeneck | T. Mayne | J. Goldstein | D. Rublee | An Vu
[1] G. Eisen,et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX‐2 selective inhibitor, valdecoxib , 2004, Alimentary pharmacology & therapeutics.
[2] L. Rabeneck. Measuring dyspepsia-related health in randomized trials: the Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2-specific inhibitors. , 2003, Rheumatology.
[3] D. Graham,et al. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. , 2002, Archives of internal medicine.
[4] J. Kent,et al. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis , 2002, European journal of gastroenterology & hepatology.
[5] A. Weaver,et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. , 2002, Rheumatology.
[6] J. Lefkowith,et al. Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac , 2002, Alimentary pharmacology & therapeutics.
[7] D. Recker,et al. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. , 2002, Osteoarthritis and cartilage.
[8] S. Dedhiya,et al. Reliability, validity, and responsiveness of Severity of Dyspepsia Assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy , 2002, American Journal of Gastroenterology.
[9] K. Cook,et al. SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health. , 2001, Journal of clinical epidemiology.
[10] M. Färkkilä,et al. Impact of non-steroidal anti-inflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease. , 2001, Scandinavian journal of gastroenterology.
[11] K. Lapane,et al. The effect of nonsteroidal anti-inflammatory drugs on the use of gastroprotective medication in people with arthritis. , 2001, The American journal of managed care.
[12] R. Makuch,et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.
[13] G. Harewood. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. , 1999, The New England journal of medicine.
[14] M. Griffin,et al. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. , 1998, The American journal of medicine.
[15] B. Dijkmans,et al. The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis , 1996, Clinical Rheumatology.
[16] P. Unge,et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. , 1996, Scandinavian journal of gastroenterology.
[17] H T Hatoum,et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. , 1996, Archives of internal medicine.
[18] D. Graham,et al. Dyspepsia in NSAID Users: The Size of the Problem , 1989, Journal of clinical gastroenterology.
[19] J. Bijlsma. Treatment of NSAID‐induced gastrointestinal lesions with cimetidine: an international multicentre collaborative study , 1988, Alimentary pharmacology & therapeutics.
[20] B. Bloom. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. , 1988, The American journal of medicine.
[21] S. Dedhiya,et al. Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy. , 2002 .
[22] Lise,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[23] S. Kong,et al. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice. , 2000, Therapie.
[24] R. Moore,et al. Cost of NSAID adverse effects to the UK National Health Service , 1999 .